Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Review, H2 2016

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Review, H2 2016', provides in depth analysis on Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Overview 6

Therapeutics Development 7

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Products under Development by Stage of Development 7

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Products under Development by Therapy Area 8

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Products under Development by Indication 9

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Products under Development by Companies 12

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Products under Development by Universities/Institutes 14

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Companies Involved in Therapeutics Development 23

NsGene A/S 23

UniQure N.V. 24

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Drug Profiles 25

AMT-140-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Drugs for Neurodegenerative Diseases-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

LAUR-301-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

NsG-0301-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Recombinant Protein to Activate GDNF for Brain Ischemia-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

smilagenin-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Dormant Projects 35

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Featured News & Press Releases 36

Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy 36

Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 36

Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane 37

Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 38

Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease 39

Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 40

Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 41

Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 42

Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 42

Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 43

Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 43

Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease 44

Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 45

Jun 05, 2007: Phytopharm plc Presents Cogane Data At '11th International Congress Of Parkinson's Disease And Movement Disorders' 45

Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by NsGene A/S, H2 2016 23

Pipeline by UniQure N.V., H2 2016 24

Dormant Projects, H2 2016 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

NsGene A/S, UniQure N.V.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Therapeutic Products under Development, Key Players in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Therapeutics, Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Pipeline Overview, Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Pipeline, Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com